SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

Abstract

From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.

Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients

“…The strength of our study lies in the large group size of the analyzed patients. According to our knowledge, there is only one report in the literature evaluating children receiving TIXA/CILGA [25]. Single-center observational study by Hijano et al presented findings involving 24 pediatric patients who received TIXA/CILGA [25].…”

“…According to our knowledge, there is only one report in the literature evaluating children receiving TIXA/CILGA [25]. Single-center observational study by Hijano et al presented findings involving 24 pediatric patients who received TIXA/CILGA [25]. The results showed that TIXA/CILGA was well-tolerated, with no serious AEs reported, and injection site pain was the most common side effect.…”